Skip to main content

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Trial Status: Complete

This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.

Inclusion Criteria

  • histologically or cytologically proven diagnosis of non-small cell lung cancer
  • positive for the ALK fusion gene (test provided by a central laboratory)
  • must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug
  • tumors must be measurable

Exclusion Criteria

  • prior treatment with PF-02341066
  • current treatment in another clinical trial

Arizona

Scottsdale
Mayo Clinic in Arizona
Status: WITHDRAWN

California

Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: COMPLETED
Orange
UC Irvine Health / Chao Family Comprehensive Cancer Center
Status: COMPLETED
Palo Alto
Stanford Cancer Institute Palo Alto
Status: COMPLETED
Sacramento
University of California Davis Comprehensive Cancer Center
Status: COMPLETED
San Diego
UC San Diego Medical Center - Hillcrest
Status: COMPLETED

Colorado

Aurora
University of Colorado Hospital
Status: COMPLETED

Connecticut

New Haven
Yale University
Status: COMPLETED

Florida

Tampa
Moffitt Cancer Center
Status: COMPLETED

Georgia

Atlanta
Emory University Hospital / Winship Cancer Institute
Status: ADMINISTRATIVELY_COMPLETE

Illinois

Chicago
University of Chicago Comprehensive Cancer Center
Status: COMPLETED

Indiana

Indianapolis
Indiana University / Melvin and Bren Simon Cancer Center
Status: COMPLETED

Maryland

Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: COMPLETED

Massachusetts

Boston
Beth Israel Deaconess Medical Center
Status: COMPLETED
Dana-Farber Cancer Institute
Status: COMPLETED
Massachusetts General Hospital Cancer Center
Status: COMPLETED

Michigan

Detroit
Wayne State University / Karmanos Cancer Institute
Status: ADMINISTRATIVELY_COMPLETE

Missouri

Saint Louis
Siteman Cancer Center at Washington University
Status: COMPLETED

Nebraska

Omaha
University of Nebraska Medical Center
Status: COMPLETED

New Hampshire

Lebanon
Dartmouth Hitchcock Medical Center
Status: COMPLETED

New York

New York
Memorial Sloan Kettering Cancer Center
Status: COMPLETED
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: COMPLETED

North Carolina

Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: COMPLETED

Ohio

Cleveland
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Status: COMPLETED
Columbus
Ohio State University Comprehensive Cancer Center
Status: COMPLETED

Oregon

Portland
OHSU Knight Cancer Institute
Status: COMPLETED

Pennsylvania

Philadelphia
Fox Chase Cancer Center
Status: CLOSED_TO_ACCRUAL_AND_INTERVENTION
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: COMPLETED

Tennessee

Nashville
Vanderbilt University / Ingram Cancer Center
Status: COMPLETED

Texas

Houston
M D Anderson Cancer Center
Status: COMPLETED

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: COMPLETED

Trial Phase Phase III

Trial Type Treatment

Lead Organization
Pfizer Inc

  • Primary ID A8081007
  • Secondary IDs NCI-2010-00112, 2009-012595-27
  • Clinicaltrials.gov ID NCT00932893